InVivo Therapeutics
InVivo Therapeutics
NVIVQ
OTC
0.34
USD
0.00%
About
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCIs). The Company's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord.
It is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. It is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine.
Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 0 |
| Three Month Average Volume | 290 |
| High Low | |
| Fifty-Two Week High | 1.3952 USD |
| Fifty-Two Week Low | 0.18913 USD |
| Fifty-Two Week High Date | 08 Aug 2023 |
| Fifty-Two Week Low Date | 27 Mar 2024 |
| Price and Volume | |
| Current Price | 0.34013 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.70% |
| Thirteen Week Relative Price Change | 0.89% |
| Twenty-Six Week Relative Price Change | -52.01% |
| Fifty-Two Week Relative Price Change | -75.36% |
| Year-to-Date Relative Price Change | -58.47% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 3.97% |
| Twenty-Six Week Price Change | -47.05% |
| Five Day Price Change | -2.48% |
| Fifty-Two Week Price Change | -71.96% |
| Year-to-Date Price Change | -54.36% |
| Month-to-Date Price Change | -6.55% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 6.44757 USD |
| Book Value Per Share (Most Recent Quarter) | 2.85678 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.44757 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.85678 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.56326 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -108322.98917 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -108322.98917 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -6.79179 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.50681 USD |
| Normalized (Last Fiscal Year) | -6.79179 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -6.79179 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.50681 USD |
| Including Extraordinary Items (Last Fiscal Year) | -6.79179 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.50681 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.6953 USD |
| Cash Per Share (Most Recent Quarter) | 2.74883 USD |
| Cash Flow Per Share (Last Fiscal Year) | -6.75295 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.37098 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.69776 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -74.07% |
| Tangible Book Value (5 Year) | 9.40% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 19.74% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 56.14% |
| EPS Change (Trailing Twelve Months) | 55.98% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -7,880,450 |
| Net Debt (Last Fiscal Year) | -15,016,100 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -9,773,190 |
| Free Cash Flow (Trailing Twelve Months) | -9,342,480 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -51.69% |
| Return on Assets (Trailing Twelve Months) | -81.32% |
| Return on Assets (5 Year) | -73.69% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -61.96% |
| Return on Equity (Trailing Twelve Months) | -98.11% |
| Return on Equity (5 Year) | -89.97% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -59.08% |
| Return on Investment (Trailing Twelve Months) | -94.35% |
| Return on Investment (5 Year) | -85.63% |